October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug regimen approved for mesothelioma in 16 years, among other approvals. Now, today’s article takes a look at the biotech companies awaiting FDA rulings in November. For more, CLICK HERE.
These Biotechs Are Awaiting FDA Rulings In November
Tags:Biotech InvestmentsBiotech SectorBiotech StocksCOVID-19 VaccineFDAInvestorRemdesivirstock market